Member Info for B2HS2L

To engage is to provoke responses containing yet more Fear, Uncertainty & Doubt.

As well proven today.

Save your time, don't engage, - you won't win 3amigo arguments.

The SP does not seem to be immaterial when CLN repayments are discussed..

B2H:

I'm touching neither mouse nor keyboard and the sound is breaking up.

If the presentation is not playing or you have a black screen, following the steps below will generally solve the issue:

SUPPORT

Refresh the page.

Try logging out and logging in again to see if this fixes the issue.

If you are using a VPN disconnect from it and connect directly to the page.

Are you on a corporate network? Log out and try to connect directly.

Do you have an anti-virus program running in the background? Disable the anti-virus software and try again.

We recommend using a modern standards-compliant browser like Chrome. Try loading the presentation in Chrome and see if you can access the presentation.

Are you using Internet Explorer, Edge Browser, DuckDuck Go, or similar? Close the browser and try loading the presentation in Chrome.

Try loading the presentation on a different device such as your phone using your phone's data connection.

+++

I'll wait for the presentation on the website.

CC - While your there get your money back. The sound breaking up.

"Anyway I am sure that's a load of old crap but *perhaps* the very first line wasn't".

TLDR goes right to the heart of why you have so many problems with your 'readership', we know we aren't missing anything.

Healthy sells 🤣🤣😁

cells even.

...and healthy sells are retained.

I wouldn't want to be pitching to Touker.

If he understood the opportunity, there'd be no opportunity left after he'd finished.

If the audience are mainly financiers, I feel they have to make their key points and dumb down the science to maximise the Leerink opportunity

BV I could see Coris being offered for sale with an optional licence to use this Affimer IP, but the patent retained within Avacta.

That may take a while to negotiate if there are interested parties in the licence.

For the removal of doubt.

https://www.divestopedia.com/definition/5786/closing-condition

Divestopedia Explains Closing Condition

Closing conditions are found in a purchase and sale agreement whereby both the target and acquirer have conditions that must be met or waived, and may also include joint conditions. Conditions may include any of the following:

Provision of closing certificates that state representations and warranties have been satisfied by both parties

Provision that each party’s representations and warranties are valid as of the closing and/or signing date

Approval by governmental authority for the transaction to take place, if applicable

Provision of fully executed ancillary documents by both parties

Condition by the seller that the buyer has met the purchase price

Deal specific conditions by the buyer that specific issues are addressed, such as pending liabilities

Joint condition that no pending litigation would prevent the deal from closing

Buyer condition that the seller obtains consent from third parties, such as suppliers

Joint condition that the transaction is legal by law

The two parties must reach agreement on the day.

++++

RNS 26.06.2024 - Portfolio Update

"The transfer of the Affimer® screening technology to the Coris operations in Belgium has enabled the Group to close the Wetherby laboratory facilities, resulting in operational cost savings."

Transcript of Shareholder meeting London 27.06.24

[01:33:59.230]-Christina Coughlin

"....Wetherby was essentially Avacta’s therapeutics, it did hold one key piece of IP, which is the use of that affirmer and antibody link within a diagnostic. We actually just had an IP meeting last night, to be honest with you. And this is what one of the questions is, where does that IP go? As you saw in the RNS, that is with Coris right now. They are the company that we purchased. The goal was to implement the Affimer IP lateral flow test..."

++++

Avacta must have moved this IP out of Coris.

Subject to customary closing conditions

Lets hope that is the formality they make it sound.

The LFT is on Trumps wish list - "We're going to be very successful with it".

What of AVA6100/6103?

"It's on our list of cost savings which Elon is hitting as I speak"

Low FAP AVA7100 will mop up after AVA6000/6103 hits the heights.

By then Avacta will no longer be owned by the likes of us.

👍

Pedro - One person wouldn't have the time to concoct and post some much incessant FUD.

To engage is to provoke responses containing yet more Fear, Uncertainty & Doubt.

Save your time and ignore.

BV

It's a networking conference rather than a scientific conference so they'll be going over old data with a view to impress and network with the various business development professionals there.

Yes agreed - IMO Avacta may want to clarify what kind of deals / situations they are not interested in,

as much as those they are.

An opportunity for Avacta attendees - through networking, to advise what constitutes an attractive deal to BP.

SB won't want to plough through many non-standard approaches they leave him cold.

Investigate showing just the one.

Just a thought, but if time is pressing and you have just pivoted into TNBC, but lack the in depth knowledge to lead a trial, (no-one suitable within Avacta R&D), there would be no choice but to look elsewhere to find these skills. Hiring a specialist would mean an unacceptable time lapse, with associated cost.

Almostrich

Thanks for spotting this issue.

"TNBC

? Not needed?"

"RNS 26.06.2024 - Avacta also announces the creation of a Scientific Advisory Board to provide expert insight and guidance on the ongoing clinical development of AVA6000 and the pipeline, including the pre|CISION™ platform. The Board will be chaired by William D. Tap MD, Chief of the Sarcoma Oncology Service at the Memorial Sloan Kettering Cancer Center in New York City."

We pivoted toward TNBC after the Scientific Advisory Board (SAB) was announced. (October 2024).

That IMO explains why there are no TNBC specialists mentioned in the SAB announcement, but does not explain why new members have not been announced.

This role may have been effectively filled by a TNBC consultancy known to SAB and company board members.

Avacta should advise sh who the TNBC members are.